The first publication outlining our efforts to utilize polymer therapeutics in antiviral therapy has been published in Chemical Communications. The article is entitled “Macromolecular Prodrugs of Ribavirin Combat Side Effects and Toxicity with No Loss of Activity of the Drug“.
Abstract
Chemi-enzymatic synthesis of ribavirin acrylate and subsequent RAFT co-polymerization with acrylic acid afforded a formulation of a broad spectrum antiviral drug which avoids accumulation in erythrocytes, the origin of the main side effect of ribavirin. In cultured macrophages the macromolecular prodrugs exhibited decreased toxicity while maintaining the anti-inflammatory action of ribavirin.
